Anti-methanogenic compositions
AssigneeSynthetic Biologics, Inc.
InventorsKlaus GOTTLIEB, Michael KALEKO, Vincent J. WACHER, Steven M. MUSKAL
Life of this patent
Estimating the term…
Abstract
The present invention relates, in part, to treatment of various diseases and disorders such as GI disorders through modulation of F420-dependent enzymes including specific enzymes involved in methanogenesis.
Claims35
A method of modulating a methanogenesis-related F420-dependent enzyme, comprising administering an effective amount of a statin, a statin analog or derivative, or a compound disclosed herein to a subject in need thereof.
A method of treating a gastrointestinal (GI) disorder, comprising administering an effective amount of a compound disclosed herein to a subject in need thereof.
A method of treating obesity, comprising administering an effective amount of a compound disclosed herein to a subject in need thereof.
A method of treating diabetes, comprising administering an effective amount of a compound disclosed herein to a subject in need thereof.
The method of any one of the above claims, wherein the subject is human.
A method of selecting a subject for treatment with a statin, a statin analog or derivative, or a compound disclosed herein, comprising:
- (i) obtaining a biological sample from the subject;
- (ii) profiling the status of an enzyme in the methanogenesis pathway in the biological sample;
- and
- (ii) selecting the subject for treatment with the statin, statin analog or derivative, or compound disclosed herein if the enzyme in the methanogenesis pathway is present at high levels in the biological sample.
A method of making an agent effective for the treatment of a methanogen-related disorder, comprising:
- (a) identifying the agent by:
- (i) contacting a test agent with an enzyme in the methanogenesis pathway;
- (ii) determining a binding affinity and/or inhibition activity of the test agent with an enzyme in the methanogenesis pathway;
- and
- (iii) selecting the test agent as a candidate agent if the result of the comparison of step (ii) indicates that the test agent is useful for the methanogen-related disorder;
- and
- (b) formulating the candidate agent for administration to the GI tract.
A pharmaceutical composition comprising one or more of Compounds (1)-(131) and a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.